GSA Capital Partners LLP Invests $1.25 Million in Perrigo Company plc $PRGO

GSA Capital Partners LLP acquired a new position in Perrigo Company plc (NYSE:PRGO) during the fourth quarter, according to its most recent 13F filing with the SEC. The firm acquired 89,433 shares of the company’s stock, valued at approximately $1,245,000. GSA Capital Partners LLP owned 0.06% of Perrigo at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Geneos Wealth Management Inc. grew its stake in shares of Perrigo by 439.1% in the first quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock valued at $27,000 after buying an additional 786 shares in the last quarter. Kestra Investment Management LLC grew its stake in shares of Perrigo by 57.1% in the second quarter. Kestra Investment Management LLC now owns 1,766 shares of the company’s stock valued at $47,000 after buying an additional 642 shares in the last quarter. Jones Financial Companies Lllp grew its stake in shares of Perrigo by 89.1% in the third quarter. Jones Financial Companies Lllp now owns 1,778 shares of the company’s stock valued at $38,000 after buying an additional 838 shares in the last quarter. CWM LLC grew its stake in shares of Perrigo by 230.0% in the fourth quarter. CWM LLC now owns 2,191 shares of the company’s stock valued at $31,000 after buying an additional 1,527 shares in the last quarter. Finally, Huntington National Bank grew its stake in shares of Perrigo by 125.0% in the third quarter. Huntington National Bank now owns 2,372 shares of the company’s stock valued at $53,000 after buying an additional 1,318 shares in the last quarter. Institutional investors and hedge funds own 95.91% of the company’s stock.

Perrigo Price Performance

Shares of PRGO opened at $11.16 on Thursday. The firm has a market cap of $1.54 billion, a price-to-earnings ratio of -0.85, a PEG ratio of 1.24 and a beta of 0.52. Perrigo Company plc has a 52 week low of $9.23 and a 52 week high of $28.43. The company has a current ratio of 2.72, a quick ratio of 1.59 and a debt-to-equity ratio of 1.45. The stock has a 50 day moving average of $10.78 and a 200-day moving average of $12.92.

Perrigo (NYSE:PRGO) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.04. The business had revenue of $841.80 million for the quarter, compared to the consensus estimate of $1.04 billion. Perrigo had a positive return on equity of 9.96% and a negative net margin of 43.50%.The business’s revenue was down 7.2% on a year-over-year basis. During the same quarter last year, the business posted $0.60 EPS. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. As a group, analysts forecast that Perrigo Company plc will post 2.14 EPS for the current year.

Perrigo Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 16th. Shareholders of record on Friday, May 29th will be paid a dividend of $0.29 per share. The ex-dividend date of this dividend is Friday, May 29th. This represents a $1.16 annualized dividend and a yield of 10.4%. Perrigo’s payout ratio is presently -8.85%.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on PRGO. Jefferies Financial Group reiterated a “hold” rating on shares of Perrigo in a research note on Thursday, February 26th. Zacks Research upgraded Perrigo from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Weiss Ratings upgraded Perrigo from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, May 13th. Finally, Canaccord Genuity Group lowered their target price on Perrigo from $20.00 to $17.00 and set a “buy” rating for the company in a research note on Friday, February 27th. One analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $19.33.

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.